-1753359025748.webp&w=3840&q=75)
2025 NOSCM | What Is New in 2025 for Thyroid Carcinoma and Thymoma?
Overview
Dr. Belisario Arango shared 2025 updates on thyroid and thymic cancers. Cabozantinib improved PFS in metastatic thyroid cancer; BRAF-mutated cases benefited from Bema+Tram. Anaplastic types saw OS gains with neoadjuvant immunotherapy. Thymic carcinoma treatments showed 80% response and 43.8-month OS.
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Belisario Arango, MD
Date of Release
July 24th, 2025
